Table 2 Demographics and clinical variables for the atrophy patterns in MCI.
From: The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment
MCI-SM- A (n = 31) | MCI-S L-P (n = 21) | MCI-ST-AD (n = 10) | MCI-S H-S (n = 18) | MCI-P M-A (n = 21) | MCI-P L-P (n = 25) | MCI-P T-AD (n = 19) | MCI-P H-S (n = 9) | |
|---|---|---|---|---|---|---|---|---|
Age** | 70,81 (7,05) | 76,94 (5,15) | 77,16 (8,37) | 76,49 (6,38) | 71,17 (7,89) | 73,97 (6,30) | 77,26 (5,66) | 77,95 (8,76) |
Education | 15,84 (2,48) | 17,00 (2,61) | 17,70 (2,26) | 14,83 (3,60) | 15,05 (3,37) | 16,24 (3,01) | 15,95 (1,99) | 14,89 (4,57) |
MMSE* | 27,58 (1,52) | 26,71 (1,45) | 25,90 (1,66) | 27,78 (1,70) | 26,67 (2,01) | 26,36 (1,58) | 26,68 (2,11) | 26,00 (1,23) |
AVLT del** | 3,87 (3,45) | 2,81 (3,12) | 1,90 (2,13) | 3,78 (3,61) | 1,48 (1,97) | 1,36 (2,20) | 1,47 (2,20) | 1,33 (1,73) |
Aβ42** | 172,43 (56,12) | 168,75 (57,49) | 162,29 (50,82) | 206,73 (60,01) | 137,45 (22,52) | 150,03 (32,12) | 145,22 (48,80) | 168,92 (51,51) |
Abnormal Aβ42 | 61% | 67% | 70% | 39% | 100% | 92% | 84% | 78% |
p-tau** | 33,19 (17,90) | 27,62 (15,30) | 32,30 (15,38) | 28,56 (12,36) | 45,05 (14,82) | 34,72 (12,93) | 42,79 (22,02) | 39,89 (15,23) |
Abnormal p-tau | 65% | 52% | 70% | 50% | 95% | 84% | 79% | 78% |
t-tau** | 88,16 (43,58) | 79,65 (47,87) | 99,80 (43,67) | 81,82 (37,79) | 129,77 (54,98) | 93,93 (30,19) | 124,36 (76,22) | 125,64 (61,91) |
Abnormal t-tau | 39% | 24% | 36% | 40% | 67% | 44% | 58% | 67% |
APOE ε4Positive N/Y | 17/14 | 12/9 | 6/4 | 11/7 | 8/13 | 8/17 | 7/12 | 4/5 |
Gender W/M | 13/18 | 4/17 | 3/7 | 6/12 | 9/12 | 9/16 | 6/13 | 4/5 |
